norepinephrine + midodrine + octreotide

This is a combination therapy consisting of three agents—norepinephrine, midodrine, and octreotide—used in the management of hepatorenal syndrome (HRS), particularly in patients with advanced liver disease. Each drug acts as a vasoconstrictor but through different mechanisms: - **Norepinephrine** is a potent alpha-adrenergic agonist that increases systemic vascular resistance and mean arterial pressure by stimulating alpha-1 adrenergic receptors on vascular smooth muscle. - **Midodrine** is an oral prodrug that forms desglymidodrine, an alpha-1 adrenergic agonist, leading to peripheral vasoconstriction and increased blood pressure. - **Octreotide** is a somatostatin analog that reduces splanchnic (intestinal) blood flow by inhibiting the release of vasodilatory peptides such as glucagon. The rationale for combining these drugs lies in their complementary effects on vascular tone. Norepinephrine provides systemic vasoconstriction; midodrine augments peripheral resistance orally; octreotide targets splanchnic circulation. This combination aims to counteract the profound arterial vasodilation seen in HRS, improve renal perfusion, and reverse acute kidney injury associated with cirrhosis. While norepinephrine or the combination of midodrine plus octreotide are both used as alternatives when terlipressin (the only FDA-approved agent for HRS) is unavailable or contraindicated, there are no standard regimens where all three drugs are used together simultaneously. Instead, clinical trials have compared norepinephrine alone versus the combination of midodrine plus octreotide[1][2][3][4][5]. There is no evidence supporting routine use of all three agents together.